Auris Medical to Present at the 29th Annual Roth Conference on March 14
March 08 2017 - 8:00AM
ZUG, Switzerland, March 8, 2017 - Auris Medical Holding AG
(NASDAQ: EARS), a clinical-stage company dedicated to developing
therapeutics that address important unmet medical needs in
otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman
and Chief Executive Officer, will present at the 29th Annual Roth
Conference on Tuesday, March 14, 2017, at 12:30 pm Pacific Time. A
live webcast of the event will be available through the Events and
Presentations page in the Investors section of the Auris Medical
website at www.aurismedical.com, and a replay of the presentation
will be available following the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology. The Company is focused on the
Phase 3 development of treatments for acute inner ear hearing loss
(AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by
way of intratympanic administration with biocompatible gel
formulations. In addition, Auris Medical is pursuing intranasal
betahistine for Meniere's disease and vestibular vertigo (AM-125)
as well as early-stage research and development projects. The
Company was founded in 2003 and is headquartered in Zug,
Switzerland. The shares of Auris Medical Holding AG trade on the
NASDAQ Global Market under the symbol "EARS."
Contact: Cindy McGee, Head of Investor Relations
and Corporate Communications, +41 61 201 1350,
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2024 to May 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From May 2023 to May 2024